Trials / Completed
CompletedNCT01678105
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Ontario Clinical Oncology Group (OCOG) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to assess the anti-cancer effects of dovitinib in this population in order to evaluate whether dovitinib is worthy of further study in patients with progressive ACC.
Conditions
- Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
- Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
- Salivary Gland Cancers
- ACC
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dovitinib | Treatment continued until Disease Progression, Toxicity, or patient withdrawal |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2012-09-03
- Last updated
- 2015-09-17
Locations
4 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01678105. Inclusion in this directory is not an endorsement.